Scientech Research LLC Acquires Shares of 20,107 Bruker Co. (NASDAQ:BRKR)

Scientech Research LLC acquired a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 20,107 shares of the medical research company's stock, valued at approximately $1,179,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in Bruker by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock worth $779,000 after purchasing an additional 177 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after buying an additional 196 shares in the last quarter. Insigneo Advisory Services LLC boosted its position in shares of Bruker by 4.7% in the fourth quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock valued at $286,000 after acquiring an additional 218 shares during the period. Arizona State Retirement System grew its stake in Bruker by 0.7% during the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after acquiring an additional 222 shares in the last quarter. Finally, CIBC Asset Management Inc increased its holdings in Bruker by 5.6% during the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock worth $248,000 after acquiring an additional 223 shares during the period. Institutional investors own 79.52% of the company's stock.

Bruker Trading Up 0.1%

Shares of BRKR traded up $0.04 during trading hours on Thursday, hitting $36.49. The company had a trading volume of 962,056 shares, compared to its average volume of 1,611,552. Bruker Co. has a 52-week low of $34.10 and a 52-week high of $78.94. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The stock's 50 day moving average price is $39.86 and its 200 day moving average price is $50.08. The firm has a market cap of $5.53 billion, a P/E ratio of 47.97, a P/E/G ratio of 2.16 and a beta of 1.23.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The business had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same quarter in the prior year, the company posted $0.53 EPS. The firm's revenue for the quarter was up 11.0% compared to the same quarter last year. On average, research analysts predict that Bruker Co. will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Monday, June 16th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.55%. Bruker's dividend payout ratio is presently 38.46%.

Wall Street Analyst Weigh In

BRKR has been the topic of several research analyst reports. UBS Group decreased their price target on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. The Goldman Sachs Group dropped their price target on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Citigroup reaffirmed a "neutral" rating and issued a $40.00 target price (down from $50.00) on shares of Bruker in a research note on Thursday. Stifel Nicolaus cut their price target on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company lowered their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Bruker has an average rating of "Hold" and an average target price of $59.10.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.